Researchers recommend specific diets for preventing colorectal cancer in high-risk groups

December 22, 2017, Centro Nacional de Investigaciones Oncológicas (CNIO)
Credit: CC0 Public Domain

Colorectal cancer is the most prevalent malignant tumour in Spain. It is known that factors such as diet and intestinal inflammation play an important role in its occurrence, but direct links between nutrients, inflammation and colorectal cancer are poorly described. Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered that the amount of protein consumed may be an important factor in the prevention of colorectal cancer in different risk groups. People already suffering from inflammatory bowel disease could benefit from a high-protein diet; however, in contrast, low protein consumption may be the best option for those people who have a genetic predisposition to develop colon cancer.

Furthermore, the article reveals that a certain type of drug used against colorectal cancer, mTORC1 inhibitors, would be more effective in patients with a genetic predisposition, which "opens up avenues for optimising and personalising treatments," the researchers write in their publication in Cell Metabolism.

Every year, more than 40,000 new cases of colorectal cancer are diagnosed in Spain, a deadly disease that is highly resistant to the treatments currently being used. Over 75 percent of cases of colorectal cancer are attributable to environmental causes, since they are not associated to genetic risk factors.

Evidence suggests that habits such as a poor diet, a lack of physical exercise and smoking may affect the digestive system and trigger inflammatory conditions such as Crohn's disease and ulcerative colitis, illnesses that often lead to colorectal cancer. However, the precise mechanisms linking diet, and colorectal cancer are not very well known.

In order to study them, Nabil Djouder, head of the Growth Factors, Nutrients and Cancer Group at the CNIO, focused upon mTORC1, a protein complex which works like a nutrient sensor. The researchers produced several genetically-modified mice in order to understand the function of this sensor in the body, and they verified the results using human samples of (derived from Crohn's disease and ) and colorectal cancer.

Some treatments for colon cancer act upon mTORC1, specifically to inhibit its activity, but at the clinic it was observed that in certain patients, mTORC1 inhibitors are practically ineffective.

Djouder's work shows that the inactivation of mTORC1 can better be beneficial in colorectal cancers with a significant genetic basis, specifically in those patients with mutations in the APC gene, which represent less than 5 percent of the total.

The dual function of mTORC1

This new study also provides information about , which encompass the vast majority and which occur in people with intestinal inflammation and without hereditary mutations in the APC gene. The researchers state that the strategy for preventing tumours in patients with intestinal inflammation should be to promote mTORC1 activity.

Researchers have found that if mTORC1 is inactivated in mice with an inflammatory disease, the cancer spreads.

When there are hereditary mutations in the APC gene and mTORC1 is inhibited, "it is likely that the combination of both types of damage generates such high chromosomal instability in the cells that they die, and the tumour does not progress," explains Djouder. However, when the inactivation of mTORC1 alone limits the damage to low chromosomal instability, an excessive inflammatory response ensues, which increases proliferation of cells with low chromosomal instability, triggering the regeneration of the damaged tissue and the development of this type of cancer.

As such, the key to this dual effect of mTORC1 may lie in the amount of damage inflicted on the cell in both situations. In other words, if the colorectal cancer is due to APC mutations, it is advisable to inhibit the mTORC1, and if it is associated to intestinal inflammation, this protein should be activated. This is where diet comes into play, since the activation of mTORC1 can be regulated through food.

High-protein or low-protein diet

Researchers describe how a high-protein diet, using whey protein supplement, a source of high proteins, for example, promotes mTORC1 activity and reduces the formation of tumours in mice with chronic gastrointestinal inflammation.

On the other hand, "a low-protein diet may be an option for preventing colorectal cancer in patients with a , for example, those who have APC mutations, whereas high-protein diet may protect patients of developing colorectal cancer with ," they state in Cell Metabolism.

"Our results may have important implications for the clinical use of mTORC1 inhibitors, such as opening up new avenues for optimising and personalising colorectal cancer treatments," they add.

Explore further: Potential new treatment for gastrointestinal cancers discovered

More information: Marta Brandt et al, mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis, Cell Metabolism (2017). DOI: 10.1016/j.cmet.2017.11.006

Related Stories

Potential new treatment for gastrointestinal cancers discovered

January 17, 2013
(Medical Xpress)—Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential ...

APC protein affects colon cancer immunity by preventing pre-cancerous inflammation

October 25, 2017
Adenomatous polyposis coli (APC) is a gene whose mutations are associated with a rare, hereditary form of colorectal cancer known as familial adenomatous polyposis. Research led by scientists at the Institut Pasteur and Inserm ...

Researchers publish new findings on influence of high-fat diet on colorectal cancer

July 6, 2017
Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known.

Gut microbes may be a risk factor for colorectal cancer

December 6, 2013
In one of the largest epidemiological studies of human gut bacteria and colorectal cancer ever conducted, a team of researchers at NYU Langone Medical Center has found a clear association between gut bacteria and colorectal ...

Decreasing cancer risk associated with inflammatory bowel disease

July 9, 2012
Inflammatory bowel disease is caused by chronic inflammation , which leads to damage of the intestinal epithelium.

Aberrant mTOR signaling impairs whole body physiology

August 11, 2014
The protein mTOR is a central controller of growth and metabolism. Deregulation of mTOR signaling increases the risk of developing metabolic diseases such as diabetes, obesity and cancer. In the current issue of the journal ...

Recommended for you

Student develops microfluidics device to help scientists identify early genetic markers of cancer

October 16, 2018
As anyone who has played "Where's Waldo" knows, searching for a single item in a landscape filled with a mélange of characters and objects can be a challenge. Chrissy O'Keefe, a Ph.D. student in the Department of Biomedical ...

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

Technique to 'listen' to a patient's brain during tumour surgery

October 16, 2018
Surgeons could soon eavesdrop on a patient's brain activity during surgery to remove their brain tumour, helping improve the accuracy of the operation and reduce the risk of impairing brain function.

Researchers elucidate roles of TP63 and SOX2 in squamous cell cancer progression

October 16, 2018
Squamous cell carcinomas (SCCs) are aggressive malignancies arising from the squamous epithelium of various organs, such as the esophagus, head and neck, lungs, and skin. Previous studies have demonstrated that two master ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.